» Articles » PMID: 26240768

Small Cell Lung Cancer Patient with Profound Hyponatremia and Acute Neurological Symptoms: An Effective Treatment with Fludrocortisone

Overview
Publisher Wiley
Specialty Oncology
Date 2015 Aug 5
PMID 26240768
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Hyponatremia is a frequent electrolyte abnormality in patients with small cell lung cancer (SCLC). Being usually asymptomatic, hyponatremia may cause symptoms like nausea, fatigue, disorientation, headache, muscle cramps, or even seizures, particularly if severe and rapid decrease of serum sodium levels occurs. Here we report a case of SCLC patient with severe hyponatremia and acute neurological symptoms that developed 2 days after the first course of second-line chemotherapy, most probably due to the release of antidiuretic hormone (ADH, also known as arginine vasopressin) during lysis of the tumour cells. Initial treatment consisted of continuous administration of hypertonic saline that resulted in improvement of patient's neurological status. However, to obtain a persistent increase in serum sodium level, pharmacological intervention with oral fludrocortisone 0.1 mg twice daily was needed. We can therefore conclude that mineralocorticoids may be used to correct hyponatremia in SCLC patients when appropriate.

Citing Articles

High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity.

Rizvi Z, Dalal R, Sadhu S, Kumar Y, Kumar S, Gupta S Sci Adv. 2021; 7(37):eabg5016.

PMID: 34516769 PMC: 8442882. DOI: 10.1126/sciadv.abg5016.


A narrative review of progress in diagnosis and treatment of small cell lung cancer patients with hyponatremia.

Wu R, Li C, Wang Z, Fan H, Song Y, Liu H Transl Lung Cancer Res. 2021; 9(6):2469-2478.

PMID: 33489807 PMC: 7815354. DOI: 10.21037/tlcr-20-1147.


Successful treatment by tolvaptan of the syndrome of inappropriate antidiuretic hormone secretion that may be associated with chemotherapy-induced tumour lysis in a patient with small-cell lung carcinoma.

Miyashita K, Matsuura S, Naoi H, Tsukui M, Koshimizu N, Suda T Respirol Case Rep. 2018; 6(3):e00296.

PMID: 29796276 PMC: 5961507. DOI: 10.1002/rcr2.296.


Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells.

Pifano M, Garona J, Capobianco C, Gonzalez N, Alonso D, Ripoll G Front Oncol. 2017; 7:11.

PMID: 28194370 PMC: 5276816. DOI: 10.3389/fonc.2017.00011.

References
1.
Vanhees S, Paridaens R, Vansteenkiste J . Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review. Ann Oncol. 2000; 11(8):1061-5. DOI: 10.1023/a:1008369932384. View

2.
Hermes A, Waschki B, Reck M . Hyponatremia as prognostic factor in small cell lung cancer--a retrospective single institution analysis. Respir Med. 2012; 106(6):900-4. DOI: 10.1016/j.rmed.2012.02.010. View

3.
Onitilo A, Kio E, Doi S . Tumor-related hyponatremia. Clin Med Res. 2007; 5(4):228-37. PMC: 2275758. DOI: 10.3121/cmr.2007.762. View

4.
Petereit C, Zaba O, Teber I, Luders H, Grohe C . A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan. BMC Pulm Med. 2013; 13:55. PMC: 3851291. DOI: 10.1186/1471-2466-13-55. View

5.
Zarzecka M, Kubicki P, Kozielski J . Hyponatraemia - evaluation of prevalence in patients hospitalized in the Pulmonary Department and prognostic significance in lung cancer patients. Pneumonol Alergol Pol. 2014; 82(1):18-24. DOI: 10.5603/PiAP.2014.0004. View